What is the official website of High Speed Ampoule Filling ?

The official website of High Speed Ampoule Filling is http://www.jublHS.com.

What is High Speed Ampoule Filling's cybersecurity risk score?

High Speed Ampoule Filling has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has High Speed Ampoule Filling experienced?

According to Rankiteo, High Speed Ampoule Filling currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has High Speed Ampoule Filling been affected by any supply chain cyber incidents ?

According to Rankiteo, High Speed Ampoule Filling has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does High Speed Ampoule Filling have SOC 2 Type 1 certification ?

According to Rankiteo, High Speed Ampoule Filling is not certified under SOC 2 Type 1.

Does High Speed Ampoule Filling have SOC 2 Type 2 certification ?

According to Rankiteo, High Speed Ampoule Filling does not hold a SOC 2 Type 2 certification.

Does High Speed Ampoule Filling comply with GDPR ?

According to Rankiteo, High Speed Ampoule Filling is not listed as GDPR compliant.

Does High Speed Ampoule Filling have PCI DSS certification ?

According to Rankiteo, High Speed Ampoule Filling does not currently maintain PCI DSS compliance.

Does High Speed Ampoule Filling comply with HIPAA ?

According to Rankiteo, High Speed Ampoule Filling is not compliant with HIPAA regulations.

Does High Speed Ampoule Filling have ISO 27001 certification ?

According to Rankiteo,High Speed Ampoule Filling is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does High Speed Ampoule Filling operate in ?

High Speed Ampoule Filling operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does High Speed Ampoule Filling have ?

High Speed Ampoule Filling employs approximately None employees people worldwide.

Does High Speed Ampoule Filling own any subsidiaries ?

High Speed Ampoule Filling presently has no subsidiaries across any sectors.

How many LinkedIn followers does High Speed Ampoule Filling have ?

High Speed Ampoule Filling's official LinkedIn profile has approximately followers.

What is the NAICS classification code for High Speed Ampoule Filling ?

High Speed Ampoule Filling is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does High Speed Ampoule Filling have a Crunchbase profile ?

No, High Speed Ampoule Filling does not have a profile on Crunchbase.

Does High Speed Ampoule Filling have a LinkedIn profile ?

Yes, High Speed Ampoule Filling maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/high-speed-ampoule-filling.

How many cybersecurity incidents has High Speed Ampoule Filling experienced ?

As of June 19, 2026, Rankiteo reports that High Speed Ampoule Filling has not experienced any cybersecurity incidents.

How many peer or competitor companies does High Speed Ampoule Filling have ?

High Speed Ampoule Filling has an estimated 5,692 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

HSAF

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

High Speed Ampoule Filling Vendor Cyber Rating & Cyber Score

jublHS.com

Add Your Compliance Badge

Jubilant HollisterStier Contract Manufacturing & Services offers ampoule filling services to the pharma and biotech industry. Batch sizes 50L to 400L. Formats 1ml, 2ml, 5ml and 10ml. [email protected]

HSAF A.I CyberSecurity Scoring

Scoring History

HSAF

High Speed Ampoule Filling CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

HSAF Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for HSAF

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for High Speed Ampoule Filling in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for High Speed Ampoule Filling in 2026.

Incident Types HSAF vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for High Speed Ampoule Filling in 2026.

Incident History - HSAF (X = Date, Y = Severity)

Loading…

SUBSIDIARY

High Speed Ampoule Filling Subsidiaries

HSAF

Pharmaceutical Manufacturing

Website: http://www.jublHS.com

Company Size: None employees

Jubilant Pharmova LimitedPharmaceutical Manufacturing

Jubilant Life Sciences Alumni NetworkPharmaceutical Manufacturing

Jubilant Biosys LimitedResearch

Jubilant Chemsys -> Jubilant Biosys LimitedPharmaceutical Manufacturing

Jubilant Generics LimitedPharmaceutical Manufacturing

Jubilant RadiopharmaPharmaceutical Manufacturing

Jubilant Pharma LimitedPharmaceutical Manufacturing

Jubilant Therapeutics IncBiotechnology

Jubilant Cadista PharmaceuticalsPharmaceutical Manufacturing

HollisterStier AllergyPharmaceutical Manufacturing

Jubilant HollisterStier CMOPharmaceutical Manufacturing

Sterile Ophthalmics & OticsPackaging & Containers

Non-Sterile Topicals and LiquidsPharmaceutical Manufacturing

Loading…

High Speed Ampoule Filling Similar Companies

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Loading…

NEWS

High Speed Ampoule Filling CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56078

SUMMARY

PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-56077

SUMMARY

PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56076

SUMMARY

PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:N

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.8

REFERENCES

CVE-2026-56075

SUMMARY

PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

CVE-2026-56074

SUMMARY

PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.

Published

Date2026-06-18

Updated

Date2026-06-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…